Viewing Study NCT04235634


Ignite Creation Date: 2025-12-25 @ 2:38 AM
Ignite Modification Date: 2025-12-31 @ 1:31 AM
Study NCT ID: NCT04235634
Status: COMPLETED
Last Update Posted: 2022-03-15
First Post: 2020-01-13
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia
Sponsor: Hannover Medical School
Organization:

Study Overview

Official Title: Evaluation of an Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia (NOMI)
Status: COMPLETED
Status Verified Date: 2022-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: REPERFUSE
Brief Summary: Minimal invasive intra-arterial prostaglandin therapy is currently being offered as an established and safe treatment approach for Non-occlusive mesenteric ischemia (NOMI). So far, there are no data that prospective evaluate clinical response parameters of this method and corresponding criteria for response.

The investigators are therefore planning a prospective observational study on NOMI patients with the aim to collect

1. routine clinical data,
2. data from advanced angigraphic imaging and
3. data from blood biomarkers of intestinal ischemia before/at implementation of intra-arterial vasodilatory therapy.

From these three data packages, the investigators hope to subsequentially derive criteria to better predict response to therapy.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: